Our mission is to improve cancer treatment and diagnosis through the discovery and development of new immune-based products. Designed to harness both arms of the native immune system, our pipeline includes both active immunotherapies and patented monoclonal antibodies (mABs). Our active immunotherapies target not only regular tumor cells, but also the cancer stem cells (CSCs) believed to cause cancer growth and recurrence. Our most advanced clinical programs are in glioblastoma multiforme (GBM). Our technologies have potential applications in many cancers with high unmet medical need, including pancreatic, ovarian, colon, small-cell lung, and multiple myeloma.
Our lead product candidate is ICT-107, a personalized, dendritic cell-based vaccine for the treatment of GBM, is currently in a Phase II study. Results of a Phase I study of ICT-107 showed prolonged survival with minimal side effects. A Phase I trial is planned with ICT-121, a dendritic cell vaccine targeting CD-133, a protein that is highly expressed on multiple tumor types. We have filed an IND for ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and CSCs, and plan to conduct a Phase IIa trial in the second half of 2013.
Our strategy is to focus primarily on the development of cancer stem cell therapeutics, and potentially to work with partners to develop and commercialize our broadly applicable monoclonal antibodies. We have strong intellectual property surrounding our monoclonal antibodies, which were designed with our proprietary discovery technology. We also have an exclusive worldwide licensing agreement with Cedars-Sinai Medical Center for our immunotherapy and cancer stem-cell technologies.